Regulation of Hippo signaling by metabolic pathways in cancer

Harvey, 2003, The drosophila mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis, Cell, 114, 457, 10.1016/S0092-8674(03)00557-9 Dey, 2020, Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine, Nat. Rev. Drug Discov., 19, 480, 10.1038/s41573-020-0070-z Koo, 2018, Interplay between YAP/TAZ and metabolism, Cell Metab., 28, 196, 10.1016/j.cmet.2018.07.010 Huang, 2005, The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of YAP, Cell, 122, 421, 10.1016/j.cell.2005.06.007 Zhao, 2010, A coordinated phosphorylation by lats and CK1 regulates YAP stability through SCF(beta-TRCP), Genes Dev., 24, 72, 10.1101/gad.1843810 Liu, 2010, The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase, J. Biol. Chem., 285, 37159, 10.1074/jbc.M110.152942 Calses, 2019, Hippo pathway in cancer: aberrant regulation and therapeutic opportunities, Trends Cancer, 5, 297, 10.1016/j.trecan.2019.04.001 Zeng, 2021, The Hippo signaling pathway in drug resistance in cancer, Cancers (Basel), 13, 10.3390/cancers13020318 Warren, 2018, YAP/TAZ activation as a target for treating metastatic cancer, Cancers (Basel), 10, 10.3390/cancers10040115 Ibar, 2020, Integration of hippo-YAP signaling with metabolism, Dev. Cell, 54, 256, 10.1016/j.devcel.2020.06.025 Cairns, 2011, Regulation of cancer cell metabolism, Nat. Rev. Cancer, 11, 85, 10.1038/nrc2981 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Montenegro, 2020, Metabolism in the tumor microenvironment, Adv. Exp. Med. Biol., 1263, 1, 10.1007/978-3-030-44518-8_1 Wang, 2015, AMPK modulates hippo pathway activity to regulate energy homeostasis, Nat. Cell Biol., 17, 490, 10.1038/ncb3113 Mo, 2015, Cellular energy stress induces AMPK-mediated regulation of YAP and the hippo pathway, Nat. Cell Biol., 17, 500, 10.1038/ncb3111 DeRan, 2014, Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein, Cell Rep., 9, 495, 10.1016/j.celrep.2014.09.036 Adler, 2013, Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of angiomotin by the LATS1/2 protein kinases, Proc. Natl. Acad. Sci. U. S. A., 110, 17368, 10.1073/pnas.1308236110 Zhao, 2011, Angiomotin is a novel hippo pathway component that inhibits YAP oncoprotein, Genes Dev., 25, 51, 10.1101/gad.2000111 Adler, 2013, Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth, J. Biol. Chem., 288, 15181, 10.1074/jbc.M112.446534 Mueckler, 2013, The SLC2 (GLUT) family of membrane transporters, Mol. Asp. Med., 34, 121, 10.1016/j.mam.2012.07.001 Cosset, 2017, Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma, Cancer Cell, 32, 856, 10.1016/j.ccell.2017.10.016 Peng, 2017, Regulation of the hippo-YAP pathway by glucose sensor O-GlcNAcylation, Mol. Cell, 68, 591, 10.1016/j.molcel.2017.10.010 Flavahan, 2013, Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake, Nat. Neurosci., 16, 1373, 10.1038/nn.3510 Libby, 2021, A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1, Cell Adhes. Migr., 15, 101, 10.1080/19336918.2021.1903684 Cox, 2018, Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth, EMBO J., 37, 10.15252/embj.2018100294 Chen, 2018, High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis, Hepatology, 67, 1823, 10.1002/hep.29663 Yang, 2017, Protein O-GlcNAcylation: emerging mechanisms and functions, Nat. Rev. Mol. Cell Biol., 18, 452, 10.1038/nrm.2017.22 Ferrer, 2016, O-GlcNAcylation in cancer biology: linking metabolism and signaling, J. Mol. Biol., 428, 3282, 10.1016/j.jmb.2016.05.028 Zhang, 2017, The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis, Nat. Commun., 8, 15280, 10.1038/ncomms15280 Kim, 2020, O-GlcNAcylation on LATS2 disrupts the hippo pathway by inhibiting its activity, Proc. Natl. Acad. Sci. U. S. A., 117, 14259, 10.1073/pnas.1913469117 Jeong, 2020, LDL receptor-related protein LRP6 senses nutrient levels and regulates hippo signaling, EMBO Rep., 21, 10.15252/embr.202050103 Liu, 2018, AMOT is required for YAP function in high glucose induced liver malignancy, Biochem. Biophys. Res. Commun., 495, 1555, 10.1016/j.bbrc.2017.12.010 Zheng, 2017, LncRNA wires up hippo and hedgehog signaling to reprogramme glucose metabolism, EMBO J., 36, 3325, 10.15252/embj.201797609 Song, 2017, FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma, Exp. Cell Res., 357, 17, 10.1016/j.yexcr.2017.04.019 Enzo, 2015, Aerobic glycolysis tunes YAP/TAZ transcriptional activity, EMBO J., 34, 1349, 10.15252/embj.201490379 Snaebjornsson, 2020, Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer, Cell Metab., 31, 62, 10.1016/j.cmet.2019.11.010 Nguyen, 2008, Liver lipid metabolism, J. Anim. Physiol. Anim. Nutr. (Berl.), 92, 272, 10.1111/j.1439-0396.2007.00752.x de Alwis, 2008, Non-alcoholic fatty liver disease: the mist gradually clears, J. Hepatol., 48, S104, 10.1016/j.jhep.2008.01.009 Schwabe, 2012, Lipids in liver disease: looking beyond steatosis, Gastroenterology, 142, 8, 10.1053/j.gastro.2011.11.004 Allen, 2019, The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study, J. Hepatol., 71, 1229, 10.1016/j.jhep.2019.08.018 Shimano, 2017, SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology, Nat Rev Endocrinol, 13, 710, 10.1038/nrendo.2017.91 Aylon, 2016, The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation, Genes Dev., 30, 786, 10.1101/gad.274167.115 Shu, 2019, A functional interaction between hippo-YAP signalling and SREBPs mediates hepatic steatosis in diabetic mice, J. Cell. Mol. Med., 23, 3616, 10.1111/jcmm.14262 Wang, 2016, Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis, Cell Metab., 24, 848, 10.1016/j.cmet.2016.09.016 Wang, 2020, Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis, Cell Metab., 31, 969, 10.1016/j.cmet.2020.03.010 Puri, 2007, A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 46, 1081, 10.1002/hep.21763 Novak, 2013, Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies, Glycobiology, 23, 1230, 10.1093/glycob/cwt059 Ye, 2017, JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity, Cancer Res., 77, 5287, 10.1158/0008-5472.CAN-17-0229 Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 Pascual, 2017, Targeting metastasis-initiating cells through the fatty acid receptor CD36, Nature, 541, 41, 10.1038/nature20791 Rada, 2020, Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?, Cell Death Dis., 11, 802, 10.1038/s41419-020-03003-w Tian, 2019, ER-residential nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy, Nat. Commun., 10, 3391, 10.1038/s41467-019-11274-x Feng, 2019, CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status, J. Exp. Clin. Cancer Res., 38, 361, 10.1186/s13046-019-1345-2 Dorsam, 2007, G-protein-coupled receptors and cancer, Nat. Rev. Cancer, 7, 79, 10.1038/nrc2069 Miller, 2012, Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP, Chem Biol, 19, 955, 10.1016/j.chembiol.2012.07.005 Yu, 2012, Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling, Cell, 150, 780, 10.1016/j.cell.2012.06.037 Luo, 2019, GPCR-Hippo signaling in cancer, Cells, 8, 10.3390/cells8050426 Tigyi, 2019, Regulation of tumor cell - microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis, Adv Biol Regul, 71, 183, 10.1016/j.jbior.2018.09.008 Gao, 2020, Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging, Nanoscale, 12, 2703, 10.1039/C9NR09452K Zhu, 2015, Proton-sensing GPCR-YAP signalling promotes cell proliferation and survival, Int. J. Biol. Sci., 11, 1181, 10.7150/ijbs.12500 Yu, 2013, Protein kinase a activates the hippo pathway to modulate cell proliferation and differentiation, Genes Dev., 27, 1223, 10.1101/gad.219402.113 Maziarz, 2020, Naturally occurring hotspot cancer mutations in Galpha13 promote oncogenic signaling, J. Biol. Chem., 295, 16897, 10.1074/jbc.AC120.014698 Yasuda, 2019, Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing notch ligand Dll4, J. Clin. Invest., 129, 4332, 10.1172/JCI121955 Wang, 2020, Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting hippo pathway, Cell Death Dis., 11, 520, 10.1038/s41419-020-2725-4 Husted, 2017, GPCR-mediated signaling of metabolites, Cell Metab., 25, 777, 10.1016/j.cmet.2017.03.008 Wu, 2019, GPCR allosteric modulator discovery, Adv. Exp. Med. Biol., 1163, 225, 10.1007/978-981-13-8719-7_10 Liu, 2020, mTOR at the nexus of nutrition, growth, ageing and disease, Nat Rev Mol Cell Biol, 21, 183, 10.1038/s41580-019-0199-y Csibi, 2012, Hippo-YAP and mTOR pathways collaborate to regulate organ size, Nat. Cell Biol., 14, 1244, 10.1038/ncb2634 Xu, 2021, YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas, Cancer Cell Int., 21, 30, 10.1186/s12935-020-01688-9 Tumaneng, 2012, YAP mediates crosstalk between the hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29, Nat. Cell Biol., 14, 1322, 10.1038/ncb2615 Sciarretta, 2015, mTORC2 regulates cardiac response to stress by inhibiting MST1, Cell Rep., 11, 125, 10.1016/j.celrep.2015.03.010 Oppermann, 2009, Large-scale proteomics analysis of the human kinome, Mol. Cell. Proteomics, 8, 1751, 10.1074/mcp.M800588-MCP200 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Artinian, 2015, Phosphorylation of the hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP signaling, resulting in enhanced glioblastoma growth and invasiveness, J. Biol. Chem., 290, 19387, 10.1074/jbc.M115.656587 Holmes, 2021, mTORC2-mediated direct phosphorylation regulates YAP activity promoting glioblastoma growth and invasive characteristics, Neoplasia, 23, 951, 10.1016/j.neo.2021.07.005 Lee, 2018, Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of yap, Nat. Commun., 9, 4962, 10.1038/s41467-018-07338-z Zhou, 2019, YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway, Cancer Cell Int., 19, 179, 10.1186/s12935-019-0898-7 Lin, 2015, The hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies, Nat. Genet., 47, 250, 10.1038/ng.3218 Dankort, 2009, Braf(V600E) cooperates with pten loss to induce metastatic melanoma, Nat. Genet., 41, 544, 10.1038/ng.356 <collab>Cancer Genome Atlas Research, 2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404 Yun, 2019, Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer, EMBO Mol. Med., 11, 10.15252/emmm.201910581 Xu, 2010, CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma, Cancer Res., 70, 2455, 10.1158/0008-5472.CAN-09-2505 Li, 2018, Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway, Cancer Cell, 34, 893, 10.1016/j.ccell.2018.11.006 Hsu, 2019, Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), Int. J. Mol. Sci., 20, 10.3390/ijms20153821 Nguyen, 2019, YAP/TAZ signaling and resistance to cancer therapy, Trends Cancer, 5, 283, 10.1016/j.trecan.2019.02.010 Chan, 2016, Autopalmitoylation of TEAD proteins regulates transcriptional output of the hippo pathway, Nat. Chem. Biol., 12, 282, 10.1038/nchembio.2036 Barry, 2021, Recent therapeutic approaches to modulate the hippo pathway in oncology and regenerative medicine, Cells, 10, 10.3390/cells10102715 Tang, 2021, Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma, Mol. Cancer Ther., 20, 986, 10.1158/1535-7163.MCT-20-0717 Holden, 2020, Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling, Cell Rep., 31, 10.1016/j.celrep.2020.107809 Zhou, 2018, Circular RNAs (circRNAs) in cancer, Cancer Lett., 425, 134, 10.1016/j.canlet.2018.03.035 Zheng, 2019, A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via hippo-YAP signaling, Mol. Cancer, 18, 47, 10.1186/s12943-019-1010-6 Li, 2020, The interaction between ferroptosis and lipid metabolism in cancer, Signal Transduct Target Ther, 5, 108, 10.1038/s41392-020-00216-5 Wu, 2019, Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling, Nature, 572, 402, 10.1038/s41586-019-1426-6 Zhu, 2016, Proton-sensing GPCR-YAP signalling promotes cancer-associated fibroblast activation of mesenchymal stem cells, Int. J. Biol. Sci., 12, 389, 10.7150/ijbs.13688 Luo, 2014, Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling, Oncogene, 33, 2768, 10.1038/onc.2013.233